Simple jQuery Dropdowns
Please use this identifier to cite or link to this item:
Title: Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2B6 and Efavirenz-Containing Antiretroviral Therapy
Authors: Zeruesenay Desta
Roseann S. Gammal
Li Gong
Michelle Whirl-Carrillo
Aditya H. Gaur
Chonlaphat Sukasem
Jennifer Hockings
Alan Myers
Marelize Swart
Rachel F. Tyndale
Collen Masimirembwa
Otito F. Iwuchukwu
Sanika Chirwa
Jeffrey Lennox
Andrea Gaedigk
Teri E. Klein
David W. Haas
Fairleigh Dickinson University
University of Texas Health Science Center at Houston
Meharry Medical College
Indiana University School of Medicine Indianapolis
Cleveland Clinic Foundation
St. Jude Children's Research Hospital
University of Toronto
Faculty of Medicine, Ramathibodi Hospital, Mahidol University
Massachusetts College of Pharmacy and Health Sciences
Stanford University
Vanderbilt University School of Medicine
Emory University School of Medicine
Division of Clinical Pharmacology
Wilkins Hospital
Keywords: Medicine
Issue Date: 1-Oct-2019
Citation: Clinical Pharmacology and Therapeutics. Vol.106, No.4 (2019), 726-733
Abstract: © 2019 The Authors Clinical Pharmacology & Therapeutics  © 2019 American Society for Clinical Pharmacology and Therapeutics The HIV type-1 nonnucleoside reverse transcriptase inhibitor, efavirenz, is widely used to treat HIV type-1 infection. Efavirenz is predominantly metabolized into inactive metabolites by cytochrome P450 (CYP)2B6, and patients with certain CYP2B6 genetic variants may be at increased risk for adverse effects, particularly central nervous system toxicity and treatment discontinuation. We summarize the evidence from the literature and provide therapeutic recommendations for efavirenz prescribing based on CYP2B6 genotypes.
ISSN: 15326535
Appears in Collections:Scopus 2019

Files in This Item:
There are no files associated with this item.

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.